Please assess the completion status of the following clinical trial:

Trial Title: Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Hepatitis C virus (HCV) genotype 1a or 1b~* Males and females, ≥18 years of age~* HCV RNA ≥10,000 IU/mL~* Participants with compensated cirrhosis are permitted~  * Advanced fibrosis (F3/F4) is capped at approximately 35% of the total treated population with a minimum of 20% F4 patients~ * If no cirrhosis, a liver biopsy within 3 years prior to enrollment~ * If cirrhosis is present, any prior liver biopsy~Key Exclusion Criteria:~* Liver or any other transplant (other than cornea and hair)~* Evidence of a medical condition contributing to chronic liver disease other than HCV infection~* Current or known history of cancer, (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment~* Evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy~* Patients infected with HIV or hepatitis B virus~* Gastrointestinal disease impacting absorption of study drug~* Uncontrolled diabetes or hypertension~* Prior exposure to an HCV direct-acting agent~* Any criteria that would exclude the patient from receiving ribavirin~* Absolute neutrophil count \<1.5\*1,000,000,000 cells/L (\<1.2\*1,000,000,000 cells/L for Black/African Americans)~* Platelets \<90\*1,000,000,000 cells/L~* Hemoglobin \<12 g/dL for females, \<13 g/dL for males~* Alanine aminotransferase ≥5\*upper limit of normal~* In patients without cirrhosis, total bilirubin ≥2 mg/dL unless patient has a documented history of Gilbert's disease~* In patients with cirrhosis, total bilirubin o ≥1.5 mg/dL~* International normalized ratio ≥1.7~* QTcF or QTcB \>500 mSec~* Creatinine clearance ≤50 mL/min~* Alpha fetoprotein (AFP) \>100 ng/mL OR~* AFP ≥50 ng/mL and ≤100 ng/mL requiring liver ultrasound~* Albumin \<3.5 g/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir (Type: EXPERIMENTAL): Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
- Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin (Type: EXPERIMENTAL): Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing \<75 kg received a total ribavirin dose of 1000 mg per day; those weighing \>=75 kg received 1200 mg per day) for 12 weeks.
- Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin (Type: EXPERIMENTAL): Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing \<75 kg received a total ribavirin dose of 1000 mg per day; those weighing \>=75 kg received 1200 mg per day) for 12 weeks.
- Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin (Type: EXPERIMENTAL): Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing \<75 kg received a total ribavirin dose of 1000 mg per day; those weighing \>=75 kg received 1200 mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).